Skip to Content
Morningstar
Get 14 Days Free

Stryker Corp SYK

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Stryker Sees Robust Recovery in Procedures, and We're Leaving Our Fair Value Estimate Unchanged

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Wide-moat Stryker delivered second-quarter performance that was punctuated with sharp revenue gains over the weak prior-year period when shelter-at-home orders and rising COVID-19 viral transmission spurred many patients to delay orthopedic and other more elective procedures. Overall, the firm is on track with our full-year projections, and we’re holding steady on our fair value estimate. While some of that procedure volume recovered since the second quarter of 2020, volume levels haven’t completely returned to normal levels until this quarter, following the widespread availability of vaccines. Profitability also improved in the second quarter. While Stryker’s gross margin held up relatively well during the pandemic disruption over the last four quarters, there were notable operating margin gains as SGA expenses rose substantially slower than the top line.

Read Full Analysis

Company Profile

Business Description

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.

Contact
2825 Airview Boulevard
Kalamazoo, MI, 49002
T +1 269 385-2600
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Classic Growth
Employees 43,000

Related

Stock Strategist Industry Reports
Will Robots Take Their Place in Orthopedics?
Robots are becoming more central to the orthopedic field, but widespread adoption still faces considerable hurdles.
Debbie Wang
Stock Strategist
We Like Zimmer's Pick for CEO
We think he’ll bring a much-needed new perspective to the company.
Debbie Wang
Stock Analyst Update
Stryker Posts Another Strong Quarter
With consistency that we rarely see in medical technology, Stryker has delivered another quarter of strong growth across all three of its segments.
Debbie Wang
US Videos
Orthopedic Robots Have Promising Future
Robots from Stryker and Zimmer Biomet are worth a look.
Debbie Wang
Stock Strategist Industry Reports
Backlog Grows for Orthopedic Procedures
But the disruption caused by COVID-19 has little effect on the device industry’s moats.
Debbie Wang
Premium Article
More Stocks for the Next Decade
Given their ties with promising technologies, these companies stand to benefit in the 2020s.
Susan Dziubinski
ETF Specialist
Seeking Quality in the S&P 500
This fund favors highly profitable firms with durable competitive advantages.
Alex Bryan
Fund Times
Despite Manager Departure, This Fund Remains Appealing
Silver-rated Jensen Quality Growth is losing one of its skippers, but the fund has maintained its disciplined approach--and outperformance--through other departures.
Greg Carlson
US Videos
This Medical Device Maker Is Ankles and Shoulders Ahead
Stryker management has shown foresight by investing in orthopedic extremities and robotics, which will support its wide moat going forward.
Debbie Wang
Investing Specialists
Ultimate Stock-Pickers: Top 10 Buys and Sells
Ahead of the sell-off, top managers were cautious in adding to positions and continued to sell fully valued, flawed, or more liquid securities to meet redemption requests.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists
Ultimate Stock-Pickers: Top Managers' High-Conviction Picks
Before the market turmoil of 2016, buying activity remained low, but these top managers did put some money to work in firms with defensible economic moats.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists
Top 10 Buys and Sells by the Ultimate Stock-Pickers
A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.
The Morningstar Ultimate Stock-Pickers Team
Stock Strategist Industry Reports
Tides Turn for These Orthopedic Firms
Industry dynamics are shifting in the wake of Zimmer's Biomet acquisition.
Debbie Wang
Quarter-End Insights
Our Outlook for Health-Care Stocks
Med-tech multinationals look to the East for growth in China.
Debbie Wang
Quarter-End Insights
Our Outlook for the Credit Markets
Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.
David Sekera
Stock Strategist
Covidien's Wide-Moat Device Business Positioned Well for Long-Term Growth
R&D investments and a narrowed focus have widened the firm's competitive advantages.
Alex Morozov
Credit Insights
Mini-Crisis in Cyprus Fails to Alarm Investors
For the most part, the credit markets were unfazed by the news out of Cyprus and likewise indifferent to the lower-than-expected earnings and weak guidance from FedEx and Oracle.
David Sekera
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
Technology names dominated our list of top-10 purchases, with Microsoft not only being a top-10 holding for our managers, but one of the highest-conviction purchases during the most recent period.
The Morningstar Ultimate Stock-Pickers Team
US Videos
Finding Value in Health Care After the Election
Tuesday's election eliminated some uncertainty around health-care reform, but the market is still undervaluing several firms in the sector, say Morningstar's Alex Morozov and Matt Coffina.
Jeremy Glaser
Stock Strategist Industry Reports
Pharma Spin-Off Should Unlock Value of Covidien's Well-Positioned Device Business
The market's not accounting for attractive growth prospects.
Alex Morozov

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.